nach oben

Current Geriatrics Reports

Erschienen in:

23.05.2017 | Geriatric Urology (H Richter, Section Editor)

Procedure-Based Management of Urgency Urinary Incontinence in the Older Woman

verfasst von: Christine M. Chu, Chiara Ghetti

Erschienen in: Current Geriatrics Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Urgency urinary incontinence (UUI) has a significant impact on the physical function and quality of life of women. When conservative treatments fail, procedure-based management can be used to treat refractory symptoms. We review recent updates on the efficacy and complications of these interventions with focus on older adults.

Recent Findings

In high quality studies, intradetrusor botulinum toxin injections and sacral neuromodulation (SNM) result in improvement in frequency of UUI episodes. Adverse effects are slightly elevated in older women, but benefits generally outweigh risks. More evidence is needed to help inform the choice between botulinum toxin injections and SNM with regard to safety and efficacy. Percutaneous tibial nerve stimulation (PTNS) shows efficacy and low adverse events, though high quality studies are few. More evidence is needed to support its use as a first-line intervention for refractory UUI, especially in older women. Surgical intervention is associated with significant complications and is only an option in those who have failed all other interventions.

Summary

Procedure-based interventions are effective in addressing UUI. Botulinum toxin injections and SNM should be considered after conservative management has failed. PTNS, with its low morbidity, could be considered before botulinum toxin and SNM if future studies support its efficacy, especially in older women. Future directions should aim to examine patient-reported long-term outcomes, especially in older adults, and decrease morbidity, which may increase the safety profile in older adults.

Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95. doi:10.1016/j.eururo.2013.08.031.CrossRefPubMed

Komesu YM, Schrader RM, Ketai LH, Rogers RG, Dunivan GC. Epidemiology of mixed, stress, and urgency urinary incontinence in middle-aged/older women: the importance of incontinence history. Int Urogynecol J. 2016;27(5):763–72.CrossRefPubMed

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–33.CrossRefPubMed

Coyne KS, Sexton CC, Clemens JQ, Thompson CL, Chen CI, Bavendam T, et al. The impact of OAB on physical activity in the United States: results from OAB-POLL. Urology. 2013;82(4):799–806. doi:10.1016/j.urology.2013.05.035.CrossRefPubMed

Nilsson M, Lalos O, Lindkvist H, Lalos A. How do urinary incontinence and urgency affect women’s sexual life? Acta Obstet Gynecol Scand. 2011;90(6):621–8. doi:10.1111/j.1600-0412.2011.01120.x.CrossRefPubMed

Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. Aust J Physiother. 2009;55(2):89–95.CrossRefPubMed

Holroyd-Leduc JM, Mehta KM, Covinsky KE. Urinary incontinence and its association with death, nursing home admission, and functional decline. J Am Geriatr Soc. 2004;52(5):712–8.CrossRefPubMed

Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367–74.CrossRefPubMed

Chu CM, Harvie HS, Smith AL, Arya LA, Andy UU. The impact of treatment of overactive bladder on physical activity limitations. J Women’s Health (Larchmt). 2016;25(8):801–5. doi:10.1089/jwh.2015.5643.CrossRef

10.

Esin E, Ergen A, Cankurtaran M, Yavuz BB, Halil M, Ulger Z, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment Health. 2015;19(3):217–23. doi:10.1080/13607863.2014.922528.CrossRefPubMed

11.

Lee LK, Goren A, Zou KH, Odell K, Russell D, Araiza AL, et al. Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder. Int J Clin Pract. 2016;70(1):66–81. doi:10.1111/ijcp.12758.CrossRefPubMed

12.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.CrossRefPubMed

13.

Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. Int Urogynecol J. 2012;23(8):975–82. doi:10.1007/s00192-012-1682-6.CrossRefPubMed

14.

Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol. 2016;8:113–22. doi:10.2147/RRU.S93636.PubMedPubMedCentral

15.

Kim H, Yoshida H, Hu X, Saito K, Yoshida Y, Kim M, et al. Association between self-reported urinary incontinence and musculoskeletal conditions in community-dwelling elderly women: a cross-sectional study. Neurourol Urodyn. 2015;34(4):322–6. doi:10.1002/nau.22567.CrossRefPubMed

16.

Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract. 2010;64(9):1287–93. doi:10.1111/j.1742-1241.2010.02442.x.CrossRefPubMed

17.

•• Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56. doi:10.1016/j.eururo.2013.04.001. Important large RCT showing efficacy of botulinum toxin versus placebo.CrossRefPubMed

18.

•• Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13. doi:10.1056/NEJMoa1208872. The ABC trial is an important RCT comparing the efficacy of sacral neuromodulation versus botulinum toxin injection.CrossRefPubMedPubMedCentral

19.

• Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Kan F, Thiery E. Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology. 2016;94:57–63. doi:10.1016/j.urology.2016.04.024. Long-term (3-year) follow-up of an RCT examining those undergoing successful sacral neuromodulation implantation.CrossRefPubMed

20.

•• Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74. doi:10.1001/jama.2016.14617. The ROSETTA trial is an important RCT comparing the efficacy of sacral neuromodulation versus medication.CrossRefPubMedPubMedCentral

21.

•• Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30. doi:10.1002/nau.22544. The InSite trial is an important RCT comparing the efficacy of sacral neuromodulation versus medication.CrossRefPubMed

22.

• Peters KM, Carrico DJ, MacDiarmid SA, Wooldridge LS, Khan AU, McCoy CE, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn. 2013;32(1):24–9. doi:10.1002/nau.22266. Prospective extension of the SUmiT trial examining the sustained efficacy of PTNS at 3 years of follow-up.CrossRefPubMed

23.

• Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, et al. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–6. doi:10.1016/j.ejogrb.2015.05.014. One of few RCTs comparing the efficacy of PTNS to medication.CrossRefPubMed

24.

• Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Investig. 2013;75(4):230–4. doi:10.1159/000350216. One of few RCTs comparing the efficacy of PTNS to medication.CrossRef

25.

• El-Azab AS, Moeen AM. The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty. Arab J Urol. 2013;11(4):344–9. doi:10.1016/j.aju.2013.07.003. A small but interesting trial comparing a newer, increasingly used treatment (botulinum toxin) and an older technique (augmentation cystoplasty).CrossRefPubMedPubMedCentral

26.

Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol. 2000;164(3 Pt 1):692–7.CrossRefPubMed

27.

Cox L, Cameron AP. OnabotulinumtoxinA for the treatment of overactive bladder. Res Rep Urol. 2014;6:79–89. doi:10.2147/RRU.S43125.PubMedPubMedCentral

28.

Sahai A, Dowson C, Khan MS, Dasgupta P, GKT Botulinum Study Group. Repeated injections of botulinum toxin—a for idiopathic detrusor overactivity. Urology. 2010;75(3):552–8. doi:10.1016/j.urology.2009.05.097.CrossRefPubMed

29.

Botox® (onabotulinumtoxinA). Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103000s5232lbl.pdf.

30.

Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57. doi:10.1016/j.eururo.2012.03.005.CrossRefPubMed

31.

Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–22. doi:10.1016/j.juro.2008.03.028.CrossRefPubMedPubMedCentral

32.

Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61(3):520–9. doi:10.1016/j.eururo.2011.10.028.CrossRefPubMed

33.

Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22. doi:10.1016/j.juro.2010.08.021.CrossRefPubMed

34.

Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30(4):556–62. doi:10.1002/nau.21021.CrossRefPubMed

35.

Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62(3):507–14. doi:10.1016/j.eururo.2011.12.056.CrossRefPubMed

36.

•• Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93. doi:10.1016/j.juro.2012.12.022. Important large RCT showing the efficacy of botulinum toxin versus placebo.CrossRefPubMed

37.

Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791–800. doi:10.1016/j.juro.2016.03.146.CrossRefPubMed

38.

Hsiao SM, Lin HH, Kuo HC. Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome. PLoS One. 2016;11(1):e0147137. doi:10.1371/journal.pone.0147137.CrossRefPubMedPubMedCentral

39.

Visco AG, Brubaker L, Jelovsek JE, Wilson TS, Norton P, Zyczynski HM, et al. Adherence to oral therapy for urgency urinary incontinence: results from the Anticholinergic Versus Botox Comparison (ABC) Trial. Female Pelvic Med Reconstr Surg. 2016;22(1):24–8. doi:10.1097/SPV.0000000000000215.CrossRefPubMedPubMedCentral

40.

Miotla P, Cartwright R, Skorupska K, Bogusiewicz M, Markut-Miotla E, Futyma K, et al. Urinary retention in female OAB after intravesical botox injection: who is really at risk? Int Urogynecol J. 2016. Osborn Neuro Uro 2015.

41.

Osborn DJ, Kaufman MR, Mock S, Guan MJ, Dmochowski RR, Reynolds WS. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34(7):675–8. doi:10.1002/nau.22642.CrossRefPubMed

42.

Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189(5):1804–10. doi:10.1016/j.juro.2012.11.089.CrossRefPubMed

43.

Jiang YH, Liao CH, Tang DL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS One. 2014;9(8):e105989. doi:10.1371/journal.pone.0105989.CrossRefPubMedPubMedCentral

44.

Davis NF, Burke JP, Redmond EJ, Elamin S, Brady CM, Flood HD. Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J. 2015;26(3):313–9. doi:10.1007/s00192-014-2499-2.CrossRefPubMed

45.

Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn. 2016;35(6):717–23. doi:10.1002/nau.22780.CrossRefPubMed

46.

Avallone MA, Sack BS, El-Arabi A, Guralnick ML, O’Connor RC. Less is more—a pilot study evaluating one to three intradetrusor sites for injection of onabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity. Neurouro Urodyn. 2016; doi:10.1002/nau.23052.

47.

Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65(6):1117–24. doi:10.1016/j.eururo.2014.01.036.CrossRefPubMed

48.

Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol. 2014;192(6):1743–9. doi:10.1016/j.juro.2014.07.008.CrossRefPubMed

49.

Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32(1):11–8.CrossRefPubMed

50.

Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol. 2016;8:193–9.PubMedPubMedCentral

51.

Spinelli M, Sievert KD. Latest technologic and surgical developments in using InterStim therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol. 2008;54(6):1287–96. doi:10.1016/j.eururo.2008.01.076.CrossRefPubMed

52.

Weil EHJ, Ruiz-Cerda JL, Eerdmans PHA, Janknegt RA, Bemelmans BLH, van Kerrebroeck PEV. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol. 2000;37:161–71.CrossRefPubMed

53.

Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PE. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol. 1999;162(2):352–7.CrossRefPubMed

54.

Al-Shaiji TF, Banakhar M, Hassouna MM. Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms. Adv Urol. 2011;2011:757454. doi:10.1155/2011/757454.PubMedPubMedCentral

55.

Cappellano F, Bertapelle P, Spinelli M, Catanzaro F, Carone R, Zanollo A, et al. Quality of life assessment in patients who undergo sacral neuromodulation implantation for urge incontinence: an additional tool for evaluating outcome. J Urol. 2001;166(6):2277–80.CrossRefPubMed

56.

Angioli R, Montera R, Plotti F, Aloisi A, Montone E, Zullo MA. Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up. Int Urogynecol J. 2013;24(5):789–94. doi:10.1007/s00192-012-1928-3.CrossRefPubMed

57.

Chughtai B, Sedrakyan A, Isaacs A, Lee R, Te A, Kaplan S. Long term safety of sacral nerve modulation in medicare beneficiaries. Neurourol Urodyn. 2015;34(7):659–63. doi:10.1002/nau.22618.CrossRefPubMed

58.

Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113(5):789–94. doi:10.1111/bju.12571.CrossRefPubMed

59.

Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56(6 Suppl 1):87–91.CrossRefPubMed

60.

White WM, Mobley JD 3rd, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Incidence and predictors of complications with sacral neuromodulation. Urology. 2009;73(4):731–5. doi:10.1016/j.urology.2008.11.047.CrossRefPubMed

61.

van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama Á, Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178(5):2029–34.CrossRefPubMed

62.

Peters KM, Killinger KA, Gilleran JP, Bartley J, Wolfert C, Boura JA. Predictors of reoperation after sacral neuromodulation: a single institution evaluation of over 400 patients. Neurourol Urodyn. 2015; doi:10.1002/nau.22929.

63.

Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012;13(5):327–34. doi:10.1007/s11934-012-0274-9.CrossRefPubMedPubMedCentral

64.

Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43. doi:10.1016/j.juro.2009.12.036.CrossRefPubMed

65.

Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6. doi:10.1016/j.juro.2010.06.113.CrossRefPubMed

66.

MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC, Siegel SW, Tate SB, Feagins BA. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183(1):234–40. doi:10.1016/j.juro.2009.08.160.CrossRefPubMed

67.

Yoong W, Shah P, Dadswell R, Green L. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders. Int Urogynecol J. 2013;24(5):795–9. doi:10.1007/s00192-012-1936-3.CrossRefPubMed

68.

Gonzalez S, Rondini C, Urzua MJ, Alva Rez J, Braun H, Kaplan F, et al. Effect of behavioral therapy versus transcutaneous posterior tibial nerve stimulation in the management of overactive bladder: a prospective randomized cross-over study (abstract). Int Urogynecol J Pelvic Floor Dysfunct. 2015;26(1 Suppl 1):S31–2.

69.

Siracusano S, Trombetta C, Liguori G, De Giorgi G, d’Aloia G, Di Benedetto P, Belgrano E. Laparoscopic bladder auto-augmentation in an incomplete traumatic spinal cord injury. Spinal Cord. 2000;38(1):59–61.CrossRefPubMed

70.

Gross M, Boone TB, Appell RA. Surgical management of overactive bladder. Curr Urol Rep. 2002;3(5):388–95.CrossRefPubMed

71.

Mundy AR, Stephenson TP. “Clam” ileocystoplasty for the treatment of refractory urge incontinence. Br J Urol. 1985;57(6):641–6.CrossRefPubMed

72.

Awad SA, Al-Zahrani HM, Gajewski JB, Bourque-Kehoe AA. Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. Br J Urol. 1998;81(4):569–73.CrossRefPubMed

73.

Flood HD, Malhotra SJ, O’Connell HE, Ritchey MJ, Bloom DA, McGuire EJ. Long-term results and complications using augmentation cystoplasty in reconstructive urology. Neurourol Urodyn. 1995;14(4):297–309.CrossRefPubMed

74.

Aslam MZ, Agarwal M. Detrusor myectomy: long-term functional outcomes. Int J Urol. 2012;19(12):1099–102. doi:10.1111/j.1442-2042.2012.03111.x.CrossRefPubMed

75.

Cheng KC, Kan CF, Chu PS, Man CW, Wong BT, Ho LY, Au WH. Augmentation cystoplasty: urodynamic and metabolic outcomes at 10-year follow-up. Int J Urol. 2015;22(12):1149–54. doi:10.1111/iju.12943.CrossRefPubMed

76.

Osborn DJ, Dmochowski RR, Kaufman MR, Milam DF, Mock S, Reynolds WS. Cystectomy with urinary diversion for benign disease: indications and outcomes. Urology. 2014;83(6):1433–7. doi:10.1016/j.urology.2014.02.030.CrossRefPubMed

77.

Brown ET, Osborn D, Mock S, Ni S, Graves AJ, Milam L, et al. Perioperative complications of conduit urinary diversion with concomitant cystectomy for benign indications: a population-based analysis. Neurourol Urodyn. 2016; doi:10.1002/nau.23135.

Titel: Procedure-Based Management of Urgency Urinary Incontinence in the Older Woman
verfasst von: Christine M. Chu
Chiara Ghetti
Publikationsdatum: 23.05.2017
Verlag: Springer US
Erschienen in: Current Geriatrics Reports / Ausgabe 2/2017
Elektronische ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-017-0205-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Procedure-Based Management of Urgency Urinary Incontinence in the Older Woman

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Non-surgical and Surgical Management of Pelvic Organ Prolapse in the Older Woman

Epidemiology, Pathophysiology and Management of Fecal Incontinence in the Older Woman

Perioperative Management of Older Women in Urogynecologic Surgery

Surgical Treatment and Outcomes for the Management of Stress Urinary Incontinence in the Older Woman

The Relationship Between Urinary Incontinence, Mobility Limitations, and Disability in Older Women

Nonsurgical Management of Urinary Incontinence in Older Women

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin